Research and clinical applications of cancer genome sequencing

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 1, 2013, Pages 3-10

  Ku, Chee S ^a   Cooper, David N ^b   Zioga, Demosthenes E ^c   Halkia, Eugenia ^d   Tzaphlidou, Margaret ^c   Roukos, Dimitrios H ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

^d METAXA Cancer Memorial Hospital   (Greece)

Author keywords

cancer genome; clinical diagnostics; hereditary cancer syndrome; mutational patterns; next generation sequencing; somatic mutation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA6; PROTEIN P53; TRANSCRIPTION FACTOR NFAT3;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CHROMOSOME REARRANGEMENT; EXOME; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENOME; GENOME ANALYSIS; GYNECOLOGIC CANCER; HUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; TECHNOLOGY; UTERUS CARCINOMA;

BREAST NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GENOME, HUMAN; HUMANS; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84873094352     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835af17c     Document Type: Review

References (24)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:719-724.
2. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331:1553-1558.
3. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9:415-428.
4. Metzker ML. Sequencing technologies: the next generation. Nat Rev Genet 2010; 11:31-46.
5. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11:685-696.
6. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012; 25:1055-1068.
7. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324:217.
8. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43:663-667.
9. Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480:99-103.
10. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012; 104:1503-1513.
11. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
12. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400-404.
13. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq Provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012; 14:357-366.
14. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010; 107:12629-12633.
15. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011; 108:18032-18037.
16. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011; 305:1577-1584.
17. Ku CS, Wu M, Cooper DN, et al. Technological advances in DNA sequence enrichment and sequencing for germline genetic diagnosis. Expert Rev Mol Diagn 2012; 12:159-173.
18. Ku CS, Cooper DN. Exome sequencing: a transient technology for molecular diagnostics? Expert Rev Mol Diagn 2012; 12:211-214.
19. Wong KM, Hudson TJ, McPherson JD. Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet 2011; 12:407-430.
20. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405-409.
21. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353-360.
22. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011; 305:1568-1576.
23. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3:111ra121.
24. Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30:434-439.